Wounds, ClosureNCT00282633
Wound Closure Techniques
A study testing Dermabond in people with Wounds, Closure, run by Hartford Hospital at 1 site in United States.
Trial summary
A Comparison of Skin Closure Techniques after Primary Cesarean Delivery. Traci N. Gray, M.D. and Peter F. Schnatz, D.O. A prospective, observer blinded, randomized, and controlled trial comparing Dermabond closure technique to suture closure of skin. Read more about this study
- Who is it for?
- Ages 18 to 60 years, women onlyHealthy volunteers can take part
- Conditions the study is for
- Wounds, Closure
- What is being tested?
- Dermabond
- Type of treatment
- Medical device
- How many people
- 120 participants
- Where
- 1 siteUnited States
- Study dates
- Nov 2005to Dec 2008
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 60 years
- Women only
- Healthy volunteers accepted
- Adult
Who may be able to join
- Patients undergoing a primary Cesarean Delivery
- Eighteen years of age or older
Who cannot join
- Allergy to Dermabond
- Fever pre or intra operatively
- The need for a vertical skin incision
Trial locations and contacts
1 site in 1 country.
United States1 site, 1 recruiting
- Recruiting
Hartford Hospital
Hartford, Connecticut, 06102
Traci Gray, M.D., 860-825-4623
About this study
Official title: A Comparison of Skin Closure Techniques After Primary Cesarean Delivery
A Comparison of Skin Closure Techniques after Primary Cesarean Delivery. Traci N. Gray, M.D. and Peter F. Schnatz, D.O.
A prospective, observer blinded, randomized, and controlled trial comparing Dermabond closure technique to suture closure of skin.
Read more
Study Participants: All women age 18years or older who provide informed consent prior to primary Cesarean delivery at Hartford Hospital. Women with vertical skin incisions and or who are febrile preop or intraop will be excluded.
Methods: Qualified participants will then be randomized to skin closure with either Dermabond or suture. Surgeon preference will dictate usage of 4-0 monocryl or 4-0 vicryl for skin closure for patients randomized to the suture arm.
- The circulating nurse will time all skin closures.
- The surgeon will complete a 3 question survey immediately postop.
- At the 6 week post partum visit, patients and the health care professional will complete a brief query regarding cosmetic appeal and pain. A disposable camera will be supplied to each provider office and a photo will be taken of the incision.
- All photos will be evaluated for cosmesis by physicians who will be blinded to the methods of skin closure.
Primary Outcomes: To compare the time needed to close skin. To compare cosmetic outcome after healing
Secondary Outcomes: Patient Pain scores. Provider and patient satisfaction. Responses to questions.
Read the detailed description
Introduction:
Much of the practice of surgical wound closure and subsequent care is based upon tradition and individual preference rather than science. Most patients undergoing cesarean deliveries at Hartford Hospital have a subcuticular running closure. Occasionally, patients have a staple closure, at the discretion of the operating surgeon. With newly introduced wound closure techniques, we intend to compare an approved closure technique (Dermabond) with the more traditional suture closure via a prospective, observer blinded, randomized, controlled trial.
Methods:
Study participants will include all women who provide informed consent prior to undergoing cesarean section at Hartford Hospital. Patients will be excluded from the study if they will require a vertical skin incision; are allergic to Dermabond; or have a temperature > 100.2 F preop or intraop. Qualified patients will then be randomized to skin closure with either the Dermabond wound closure technique or suture.
Closure method randomization will be performed prospectively by placing closure modality options in opaque sealed envelopes prior to the initiation of the study. The envelopes will be available in the operating room. The circulating nurse will open the envelope to reveal the randomization arm prior to skin closure and the surgeon will utilize the indicated technique. The circulating nurse will record the length of time needed to close the skin incision. The surgeon will complete a short survey immediately post operatively regarding ease of use of the closure modality as well as expected cosmetic outcome.
If a patient is randomized to suture, surgeon preference will dictate whether 4-0 vicryl or 4-0 monocryl will be used as well as whether Keith or curved needle will be utilized. Patient demographics and contact information will be obtained prior to initiation of the procedure.
Prior to initiation of surgery, the operative field will be prepared by dry shaving the site with a disposable razor then cleansing the abdomen with Betadine using sterile technique. Hibiclens soap will be substituted for patients who are sensitive or allergic to iodine. A first generation Cephalosporin will be administered ~ 30 minutes preop for patients undergoing scheduled cesarean delivery. If the procedure is unscheduled, a first generation Cephalosporin will be administered after cord clamp if the patient has not already received antibiotics preoperatively.
The patients' post operative pain medicine requirements and pain self assessment scores will be monitored during their post operative hospital course as documented in the medication logs on their charts. Most patients will be discharged on postoperative day three or four unless complications arise.
All patients will be seen in the office for a 6-week post partum follow up. A medical professional will assess their wounds. The patient and the medical professional will be queried regarding their satisfaction with cosmetic outcome of the wound. The patient will also be queried regarding continued pain medicine requirements. If the patient does not show up for their post partum visit, they will be called to obtain this information and to arrange a time for follow-up.
Each medical professional will be provided with a disposable camera. The camera will be used to take pictures of each patient's wound at the 6-week follow up visit. Specific guidelines will be provided regarding the distance and angle at which the pictures should be taken to ensure optimal and uniform photo clarity. The pictures will be reviewed at a later time by a panel of observers who will be blinded to the type of wound closure that the patient received. The observer will assess each picture for wound cosmesis and healing to provide standardized objective evaluation of wound closure outcomes.
Power and Sample Size:
The primary outcomes will be surgical time (wound closure only), patient satisfaction and blinded observer-rated cosmesis. Using a 1:3 randomization scheme, group sample sizes of 25 (test/Dermabond) and 75 (control/suture) would achieve 80% power to detect a difference of 1.0 between the null hypothesis that both group means for satisfaction and cosmesis are 3.0 ("average") and the alternative hypothesis that the mean of the Dermabond group is 2.0 ("above average") with estimated group standard deviations of 1.5 and with a significance level (alpha) of 0.05 using a two-sided, two-sample t-test.
Assuming the average closure time for the suture group is 6 minutes (SD +/-1), and hypothesizing an average closure time in the Dermabond group of 1.5 minutes (SD +/- 0.5 minutes), these sample sizes would afford better than 99% power to detect differences in surgical (closure) time between the two groups.
The Women's Health Department at Hartford Hospital performs an average of 12 procedures per week (range 10-15). If 70% of the eligible women consent to participate, it should take approximately 12 weeks to accrue the minimum number of subjects. However, if the participation rate is 80%-85%, only 10-11 weeks should be required for accrual.
Data Analysis / Statistics:
Descriptive statistics on continuous variables (e.g., height, weight, maternal age, gestational age, surgical (closure) time) will consist of means, standard deviations and 95% confidence intervals. Frequencies of race and ethnicity also will be run. To evaluate the primary outcomes between treatment arms, differences in closure time, patient satisfaction and observed healing, t-tests will be utilized. Subgroup comparisons (e.g., within the suture group between curved and Keith needles) also will be performed with t-tests. Secondary analyses of dichotomous (yes/no) variables, including surgeon responses to "Did you find this method effective?" and "Did you find this method burdensome?" will be evaluated with a c2 test. Although infections may occur and will be noted, the rate is anticipated to be so low that statistical assessment will not be necessary. Statistically significant differences will be considered as analyses resulting in p<0.05. All analyses will be performed with SPSS v. 11.5 (Chicago, IL, 2003).
- Conditions
- Wounds, Closure
- Being tested
- Dermabond
- Keywords
- Cesarean Delivery, Wound closure, Suture, Alternative therapy, Surgery
- Medical subject headings
- Wounds and Injuries
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
DermabondDevice
What is being measured
The primary outcome is the main question the study is designed to answer.
Time needed to close skin.
Cosmetic outcome after healing
Secondary outcomes (3)
Patient Pain scores.
Provider and patient satisfaction.
Responses to questions.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted27 Jan 2006 (estimated)
- Study startNov 2005
- Study completionDec 2008 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Wounds, ClosureStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind
- Who is masked
- Outcomes assessor
- Enrolment
- 120 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Hartford Hospital
- Sponsor type
- University, hospital or other
- Investigators
- Peter F. Schnatz, D.O., Principal investigator, Hartford Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00282633
- Sponsor's protocol ID
- SCHN001820HU
- Status last verified
- Oct 2007
- First submitted
- 25 Jan 2006
- Last updated
- 31 Oct 2007
- Results posted
- No
Study at a glance
From the registry record, last updated by the sponsor on 31 Oct 2007. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Comparison of Skin Closure Techniques After Primary Cesarean Delivery
- ClinicalTrials.gov ID
- NCT00282633
- Acronym / sponsor ID
- SCHN001820HU
- Conditions
- Wounds, Closure
- Keywords
- Cesarean Delivery, Wound closure, Suture, Alternative therapy, Surgery
- Study type
- Interventional
- Recruitment status
- Unknown status
- Enrolment
- 120 participants (estimated)
- Lead sponsor
- Hartford HospitalUniversity, hospital or other
- Study start
- Nov 2005
- Study completion
- Dec 2008 (estimated)
- First posted
- 27 Jan 2006 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
A Comparison of Skin Closure Techniques after Primary Cesarean Delivery. Traci N. Gray, M.D. and Peter F. Schnatz, D.O.
A prospective, observer blinded, randomized, and controlled trial comparing Dermabond closure technique to suture closure of skin.
Study Participants: All women age 18years or older who provide informed consent prior to primary Cesarean delivery at Hartford Hospital. Women with vertical skin incisions and or who are febrile preop or intraop will be excluded.
Methods: Qualified participants will then be randomized to skin closure with either Dermabond or suture. Surgeon preference will dictate usage of 4-0 monocryl or 4-0 vicryl for skin closure for patients randomized to the suture arm.
- The circulating nurse will time all skin closures.
- The surgeon will complete a 3 question survey immediately postop.
- At the 6 week post partum visit, patients and the health care professional will complete a brief query regarding cosmetic appeal and pain. A disposable camera will be supplied to each provider office and a photo will be taken of the incision.
- All photos will be evaluated for cosmesis by physicians who will be blinded to the methods of skin closure.
Primary Outcomes: To compare the time needed to close skin. To compare cosmetic outcome after healing
Secondary Outcomes: Patient Pain scores. Provider and patient satisfaction. Responses to questions.
Detailed description
Introduction:
Much of the practice of surgical wound closure and subsequent care is based upon tradition and individual preference rather than science. Most patients undergoing cesarean deliveries at Hartford Hospital have a subcuticular running closure. Occasionally, patients have a staple closure, at the discretion of the operating surgeon. With newly introduced wound closure techniques, we intend to compare an approved closure technique (Dermabond) with the more traditional suture closure via a prospective, observer blinded, randomized, controlled trial.
Methods:
Study participants will include all women who provide informed consent prior to undergoing cesarean section at Hartford Hospital. Patients will be excluded from the study if they will require a vertical skin incision; are allergic to Dermabond; or have a temperature > 100.2 F preop or intraop. Qualified patients will then be randomized to skin closure with either the Dermabond wound closure technique or suture.
Closure method randomization will be performed prospectively by placing closure modality options in opaque sealed envelopes prior to the initiation of the study. The envelopes will be available in the operating room. The circulating nurse will open the envelope to reveal the randomization arm prior to skin closure and the surgeon will utilize the indicated technique. The circulating nurse will record the length of time needed to close the skin incision. The surgeon will complete a short survey immediately post operatively regarding ease of use of the closure modality as well as expected cosmetic outcome.
If a patient is randomized to suture, surgeon preference will dictate whether 4-0 vicryl or 4-0 monocryl will be used as well as whether Keith or curved needle will be utilized. Patient demographics and contact information will be obtained prior to initiation of the procedure.
Prior to initiation of surgery, the operative field will be prepared by dry shaving the site with a disposable razor then cleansing the abdomen with Betadine using sterile technique. Hibiclens soap will be substituted for patients who are sensitive or allergic to iodine. A first generation Cephalosporin will be administered ~ 30 minutes preop for patients undergoing scheduled cesarean delivery. If the procedure is unscheduled, a first generation Cephalosporin will be administered after cord clamp if the patient has not already received antibiotics preoperatively.
The patients' post operative pain medicine requirements and pain self assessment scores will be monitored during their post operative hospital course as documented in the medication logs on their charts. Most patients will be discharged on postoperative day three or four unless complications arise.
All patients will be seen in the office for a 6-week post partum follow up. A medical professional will assess their wounds. The patient and the medical professional will be queried regarding their satisfaction with cosmetic outcome of the wound. The patient will also be queried regarding continued pain medicine requirements. If the patient does not show up for their post partum visit, they will be called to obtain this information and to arrange a time for follow-up.
Each medical professional will be provided with a disposable camera. The camera will be used to take pictures of each patient's wound at the 6-week follow up visit. Specific guidelines will be provided regarding the distance and angle at which the pictures should be taken to ensure optimal and uniform photo clarity. The pictures will be reviewed at a later time by a panel of observers who will be blinded to the type of wound closure that the patient received. The observer will assess each picture for wound cosmesis and healing to provide standardized objective evaluation of wound closure outcomes.
Power and Sample Size:
The primary outcomes will be surgical time (wound closure only), patient satisfaction and blinded observer-rated cosmesis. Using a 1:3 randomization scheme, group sample sizes of 25 (test/Dermabond) and 75 (control/suture) would achieve 80% power to detect a difference of 1.0 between the null hypothesis that both group means for satisfaction and cosmesis are 3.0 ("average") and the alternative hypothesis that the mean of the Dermabond group is 2.0 ("above average") with estimated group standard deviations of 1.5 and with a significance level (alpha) of 0.05 using a two-sided, two-sample t-test.
Assuming the average closure time for the suture group is 6 minutes (SD +/-1), and hypothesizing an average closure time in the Dermabond group of 1.5 minutes (SD +/- 0.5 minutes), these sample sizes would afford better than 99% power to detect differences in surgical (closure) time between the two groups.
The Women's Health Department at Hartford Hospital performs an average of 12 procedures per week (range 10-15). If 70% of the eligible women consent to participate, it should take approximately 12 weeks to accrue the minimum number of subjects. However, if the participation rate is 80%-85%, only 10-11 weeks should be required for accrual.
Data Analysis / Statistics:
Descriptive statistics on continuous variables (e.g., height, weight, maternal age, gestational age, surgical (closure) time) will consist of means, standard deviations and 95% confidence intervals. Frequencies of race and ethnicity also will be run. To evaluate the primary outcomes between treatment arms, differences in closure time, patient satisfaction and observed healing, t-tests will be utilized. Subgroup comparisons (e.g., within the suture group between curved and Keith needles) also will be performed with t-tests. Secondary analyses of dichotomous (yes/no) variables, including surgeon responses to "Did you find this method effective?" and "Did you find this method burdensome?" will be evaluated with a c2 test. Although infections may occur and will be noted, the rate is anticipated to be so low that statistical assessment will not be necessary. Statistically significant differences will be considered as analyses resulting in p<0.05. All analyses will be performed with SPSS v. 11.5 (Chicago, IL, 2003).
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (outcomes assessor)
Who may qualify
- Ages
- 18 to 60 years
- Sex
- Female only
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (2 listed)
- Patients undergoing a primary Cesarean Delivery
- Eighteen years of age or older
Key exclusion criteria (3 listed)
- Allergy to Dermabond
- Fever pre or intra operatively
- The need for a vertical skin incision
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Dermabond | Device | – |
Primary outcome
Time needed to close skin.
Cosmetic outcome after healing
3 secondary outcomes
Patient Pain scores.
Provider and patient satisfaction.
Responses to questions.
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 31 Oct 2007.
Related trials for Wounds, Closure
Active, not recruiting
A Study Of Cryptoglandular Fistula-in-ano And Associated Non-healing Draining Wounds With Kerecis SurgiClose
Fistula-in-ano, Draining Wound
Not yet recruiting
Effectiveness of Silver Nitrate Cauterization vs Conservative Management in Tympanic Membrane Perforation Closure
Tympanic Membrane Perforation
Not yet recruiting
Comparison of Wound Healing Duration Between Vacuum-Assisted Closure (VAC) and Conventional Dressings
Wound Healing
Active, not recruiting
Influence of Sun Protection and Linear Repair of Cutaneous Surgical Defects
Surgical Wound, Wound Heal
Recruiting
Miro3D Wound Matrix for Treatment of Diabetic Foot Ulcers
Diabetic Foot Ulcers (DFUs), Diabetic Foot
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Peter F. Schnatz, D.O. principal investigator
Hartford Hospital
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Dermabond in people with Wounds, Closure, run by Hartford Hospital at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 31 Oct 2007. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Each site lists its own contact: choose the nearest one under Trial locations. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Time needed to close skin.. The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 31 Oct 2007.